Drug Profile


Alternative Names: Auriculin; hANP (102-126); WY 47663

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scios
  • Developer Genentech; Scios
  • Class Antihypertensives; Anxiolytics; Heart failure therapies; Hormones; Natriuretic peptides
  • Mechanism of Action Atrial peptide agonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Hypertension; Renal failure

Most Recent Events

  • 06 Nov 1997 Discontinued-Clinical for Heart failure in USA (IV)
  • 06 Nov 1997 Discontinued-Clinical for Hypertension in European Union (IV)
  • 06 Nov 1997 Discontinued-Clinical for Hypertension in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top